[{"id":"a07fe804-b24b-42e5-81ce-af1dddb29fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04400383","created_at":"2021-03-09T08:59:58.256Z","updated_at":"2024-07-02T16:35:00.974Z","phase":"Phase 1","brief_title":"Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04400383","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • AB011"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2024-05-24"}]